Search research articles
Contact Us
Filters
Showing results (281-290 of 313) with videos related to
Page
of 32
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
April 30, 2016
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials
Massimo Gentile, Katja Zirlik, Stefania Ciolli, et al.
Leukemia
|
July 8, 2025
Integration of [<sup>18</sup>F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma
Riccardo Dondolin, Federico Garrou, Mohammad Almasri, et al.
Blood Advances
|
January 17, 2024
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial
Maria Gabriella Mazzucconi, Francesco Rodeghiero, Giuseppe Avvisati, et al.
European Journal of Haematology
|
October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
Fortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Haematologica
|
April 30, 2025
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients
Gregorio Barilà, Angela Grassi, Concetta Conticello, et al.
Hematological Oncology
|
February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Blood Advances
|
April 16, 2025
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort
Andrea Serafin, Alessandro Cellini, Enrica Antonia Martino, et al.
Annals of Hematology
|
October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy
Concetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Science Advances
|
January 19, 2022
Preneoplastic somatic mutations including <i>MYD88</i><sup>L265P</sup> in lymphoplasmacytic lymphoma
Sara Rodriguez, Jon Celay, Ibai Goicoechea, et al.
Cancers
|
January 11, 2022
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
Francesca Romana Mauro, Francesca Paoloni, Stefano Molica, et al.
Page
of 32
Search research articles
Search
Showing results (281-290 of 313) with videos related to
Sort By:
Page
of 32
European Journal of Cancer (Oxford, England : 1990)
|
April 30, 2016
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials
Massimo Gentile, Katja Zirlik, Stefania Ciolli, et al.
Leukemia
|
July 8, 2025
Integration of [<sup>18</sup>F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma
Riccardo Dondolin, Federico Garrou, Mohammad Almasri, et al.
Blood Advances
|
January 17, 2024
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial
Maria Gabriella Mazzucconi, Francesco Rodeghiero, Giuseppe Avvisati, et al.
European Journal of Haematology
|
October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
Fortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Haematologica
|
April 30, 2025
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients
Gregorio Barilà, Angela Grassi, Concetta Conticello, et al.
Hematological Oncology
|
February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Blood Advances
|
April 16, 2025
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort
Andrea Serafin, Alessandro Cellini, Enrica Antonia Martino, et al.
Annals of Hematology
|
October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy
Concetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Science Advances
|
January 19, 2022
Preneoplastic somatic mutations including <i>MYD88</i><sup>L265P</sup> in lymphoplasmacytic lymphoma
Sara Rodriguez, Jon Celay, Ibai Goicoechea, et al.
Cancers
|
January 11, 2022
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
Francesca Romana Mauro, Francesca Paoloni, Stefano Molica, et al.
Page
of 32